Clinical and genetic factors related to cancer-induced bone pain and bone pain relief

Emanuela Scarpi, Daniele Calistri, Pål Klepstad, Stein Kaasa, Frank Skorpen, Ragnhild Habberstad, Oriana Nanni, Dino Amadori, Marco Maltoni

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. The study objective was to evaluate whether there are clinical or genetic differences between patients with cancer-induced bone pain (CIBP) and patients with non-CIBP, and, in the CIBP group, in those with good versus poor opioid response.

Materials and Methods. A total of 2,294 adult patients with cancer who were receiving opioids for moderate or severe pain were included in the European Pharmacogenetic Opioid Study. Pain intensity and pain relief were measured using the Brief Pain Inventory. Linkage disequilibrium of 112 single nucleotide polymorphisms was evaluated in 25 candidate genes, and 43 haplotypes were assessed. Correlations among demographical factors, disease-related factors, genetic factors, CIBP, and pain relief were analyzed by logistic regression models corrected for multiple testing. Patients with bone metastases and bone/soft tissue pain were defined as having prevalent bone pain (CIBP population). This population was compared with patients who had other types of cancer pain (non-CIBP).

Results. A total of 577 patients (26.2%) had CIBP, and 1,624 patients (73.8%) had non-CIBP. Patients with CIBP had more breakthrough cancer pain episodes (64.2% vs. 56.4%, p = .001), had significantly higher pain interference in“walkingability in the past 24 hours” (p <.0001), used more adjuvant drugs (84.1% vs. 78.3%, p = .003), and had a higher, albeit nonsignificant, median overall survival (3.8 vs. 2.9 months, p = .716) than patients with non-CIBP. None of the examined haplotypes exceeded p values corrected for multiple testing for the investigated outcomes.

Conclusion. Patients with CIBP who were taking opioids had a clinical profile slightly different from that of the non-CIBP group. However, no specific genetic pattern emerged for CIBP versus non-CIBP or for responsive versus nonresponsive patients with CIBP. The Oncologist 2014;19:1276–1283

Original languageEnglish
Pages (from-to)1276-1283
Number of pages8
JournalThe oncologist
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Bone Neoplasms
Bone and Bones
Pain
Population
Opioid Analgesics
Haplotypes
Logistic Models
Neoplasms
Linkage Disequilibrium

Keywords

  • Assessment
  • Cancer-induced bone pain
  • Genetic factors
  • Haplotypes
  • Opioids
  • Palliative care

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. / Scarpi, Emanuela; Calistri, Daniele; Klepstad, Pål; Kaasa, Stein; Skorpen, Frank; Habberstad, Ragnhild; Nanni, Oriana; Amadori, Dino; Maltoni, Marco.

In: The oncologist, Vol. 19, No. 12, 01.12.2014, p. 1276-1283.

Research output: Contribution to journalArticle

Scarpi, Emanuela ; Calistri, Daniele ; Klepstad, Pål ; Kaasa, Stein ; Skorpen, Frank ; Habberstad, Ragnhild ; Nanni, Oriana ; Amadori, Dino ; Maltoni, Marco. / Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. In: The oncologist. 2014 ; Vol. 19, No. 12. pp. 1276-1283.
@article{93ae2c0a709642fe9c020b4292666b93,
title = "Clinical and genetic factors related to cancer-induced bone pain and bone pain relief",
abstract = "Objective. The study objective was to evaluate whether there are clinical or genetic differences between patients with cancer-induced bone pain (CIBP) and patients with non-CIBP, and, in the CIBP group, in those with good versus poor opioid response.Materials and Methods. A total of 2,294 adult patients with cancer who were receiving opioids for moderate or severe pain were included in the European Pharmacogenetic Opioid Study. Pain intensity and pain relief were measured using the Brief Pain Inventory. Linkage disequilibrium of 112 single nucleotide polymorphisms was evaluated in 25 candidate genes, and 43 haplotypes were assessed. Correlations among demographical factors, disease-related factors, genetic factors, CIBP, and pain relief were analyzed by logistic regression models corrected for multiple testing. Patients with bone metastases and bone/soft tissue pain were defined as having prevalent bone pain (CIBP population). This population was compared with patients who had other types of cancer pain (non-CIBP).Results. A total of 577 patients (26.2{\%}) had CIBP, and 1,624 patients (73.8{\%}) had non-CIBP. Patients with CIBP had more breakthrough cancer pain episodes (64.2{\%} vs. 56.4{\%}, p = .001), had significantly higher pain interference in“walkingability in the past 24 hours” (p <.0001), used more adjuvant drugs (84.1{\%} vs. 78.3{\%}, p = .003), and had a higher, albeit nonsignificant, median overall survival (3.8 vs. 2.9 months, p = .716) than patients with non-CIBP. None of the examined haplotypes exceeded p values corrected for multiple testing for the investigated outcomes.Conclusion. Patients with CIBP who were taking opioids had a clinical profile slightly different from that of the non-CIBP group. However, no specific genetic pattern emerged for CIBP versus non-CIBP or for responsive versus nonresponsive patients with CIBP. The Oncologist 2014;19:1276–1283",
keywords = "Assessment, Cancer-induced bone pain, Genetic factors, Haplotypes, Opioids, Palliative care",
author = "Emanuela Scarpi and Daniele Calistri and P{\aa}l Klepstad and Stein Kaasa and Frank Skorpen and Ragnhild Habberstad and Oriana Nanni and Dino Amadori and Marco Maltoni",
year = "2014",
month = "12",
day = "1",
doi = "10.1634/theoncologist.2014-0174",
language = "English",
volume = "19",
pages = "1276--1283",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "12",

}

TY - JOUR

T1 - Clinical and genetic factors related to cancer-induced bone pain and bone pain relief

AU - Scarpi, Emanuela

AU - Calistri, Daniele

AU - Klepstad, Pål

AU - Kaasa, Stein

AU - Skorpen, Frank

AU - Habberstad, Ragnhild

AU - Nanni, Oriana

AU - Amadori, Dino

AU - Maltoni, Marco

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective. The study objective was to evaluate whether there are clinical or genetic differences between patients with cancer-induced bone pain (CIBP) and patients with non-CIBP, and, in the CIBP group, in those with good versus poor opioid response.Materials and Methods. A total of 2,294 adult patients with cancer who were receiving opioids for moderate or severe pain were included in the European Pharmacogenetic Opioid Study. Pain intensity and pain relief were measured using the Brief Pain Inventory. Linkage disequilibrium of 112 single nucleotide polymorphisms was evaluated in 25 candidate genes, and 43 haplotypes were assessed. Correlations among demographical factors, disease-related factors, genetic factors, CIBP, and pain relief were analyzed by logistic regression models corrected for multiple testing. Patients with bone metastases and bone/soft tissue pain were defined as having prevalent bone pain (CIBP population). This population was compared with patients who had other types of cancer pain (non-CIBP).Results. A total of 577 patients (26.2%) had CIBP, and 1,624 patients (73.8%) had non-CIBP. Patients with CIBP had more breakthrough cancer pain episodes (64.2% vs. 56.4%, p = .001), had significantly higher pain interference in“walkingability in the past 24 hours” (p <.0001), used more adjuvant drugs (84.1% vs. 78.3%, p = .003), and had a higher, albeit nonsignificant, median overall survival (3.8 vs. 2.9 months, p = .716) than patients with non-CIBP. None of the examined haplotypes exceeded p values corrected for multiple testing for the investigated outcomes.Conclusion. Patients with CIBP who were taking opioids had a clinical profile slightly different from that of the non-CIBP group. However, no specific genetic pattern emerged for CIBP versus non-CIBP or for responsive versus nonresponsive patients with CIBP. The Oncologist 2014;19:1276–1283

AB - Objective. The study objective was to evaluate whether there are clinical or genetic differences between patients with cancer-induced bone pain (CIBP) and patients with non-CIBP, and, in the CIBP group, in those with good versus poor opioid response.Materials and Methods. A total of 2,294 adult patients with cancer who were receiving opioids for moderate or severe pain were included in the European Pharmacogenetic Opioid Study. Pain intensity and pain relief were measured using the Brief Pain Inventory. Linkage disequilibrium of 112 single nucleotide polymorphisms was evaluated in 25 candidate genes, and 43 haplotypes were assessed. Correlations among demographical factors, disease-related factors, genetic factors, CIBP, and pain relief were analyzed by logistic regression models corrected for multiple testing. Patients with bone metastases and bone/soft tissue pain were defined as having prevalent bone pain (CIBP population). This population was compared with patients who had other types of cancer pain (non-CIBP).Results. A total of 577 patients (26.2%) had CIBP, and 1,624 patients (73.8%) had non-CIBP. Patients with CIBP had more breakthrough cancer pain episodes (64.2% vs. 56.4%, p = .001), had significantly higher pain interference in“walkingability in the past 24 hours” (p <.0001), used more adjuvant drugs (84.1% vs. 78.3%, p = .003), and had a higher, albeit nonsignificant, median overall survival (3.8 vs. 2.9 months, p = .716) than patients with non-CIBP. None of the examined haplotypes exceeded p values corrected for multiple testing for the investigated outcomes.Conclusion. Patients with CIBP who were taking opioids had a clinical profile slightly different from that of the non-CIBP group. However, no specific genetic pattern emerged for CIBP versus non-CIBP or for responsive versus nonresponsive patients with CIBP. The Oncologist 2014;19:1276–1283

KW - Assessment

KW - Cancer-induced bone pain

KW - Genetic factors

KW - Haplotypes

KW - Opioids

KW - Palliative care

UR - http://www.scopus.com/inward/record.url?scp=84919402490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919402490&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0174

DO - 10.1634/theoncologist.2014-0174

M3 - Article

C2 - 25342315

AN - SCOPUS:84919402490

VL - 19

SP - 1276

EP - 1283

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 12

ER -